Evidence map›Paper›PMID 35874776›Full record

SynthesisFrontiers in immunology2022

A Barrier to Defend - Models of Pulmonary Barrier to Study Acute Inflammatory Diseases.

Anna Herminghaus, Andrey V Kozlov, Andrea Szabó, Zoltán Hantos, Severin Gylstorff, Anne Kuebart, Mahyar Aghapour, Bianka Wissuwa, Thorsten Walles, Heike Walles and 2 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. A multiplex inhalation platform to modelFrontiers in pharmacology · 2023
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Anna HerminghausDepartment of Anaesthesiology, University of Duesseldorf, Duesseldorf, Germany.
Andrey V KozlovL Boltzmann Institute for Traumatology in Cooperation with AUVA and Austrian Cluster for Tissue Regeneration, Vienna, Austria.
Andrea SzabóInstitute of Surgical Research, University of Szeged, Szeged, Hungary.
Zoltán HantosDepartment of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.
Severin GylstorffExperimental Radiology, Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Anne KuebartDepartment of Anaesthesiology, University of Duesseldorf, Duesseldorf, Germany.
Mahyar AghapourExperimental Radiology, Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Bianka WissuwaDepartment of Anaesthesiology and Intensive Care Medicine, Septomics Research Centre, Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
Thorsten WallesDepartment of Thoracic Surgery, Magdeburg University Medicine, Magdeburg, Germany.
Heike WallesResearch Campus STIMULATE, Otto-von-Guericke University, Magdeburg, Germany.
Sina M ColdeweyDepartment of Anaesthesiology and Intensive Care Medicine, Septomics Research Centre, Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
Borna ReljaExperimental Radiology, Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Otto-von-Guericke University Magdeburg · DEHeinrich Heine University Düsseldorf · DEJena University Hospital · DESechenov University · RUSemmelweis University · HUUniversity Hospital Magdeburg · DEUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary diseases represent four out of ten most common causes for worldwide mortality. Thus, pulmonary infections with subsequent inflammatory responses represent a major public health concern. The pulmonary barrier is a vulnerable entry site for several stress factors, including pathogens such as viruses, and bacteria, but also environmental factors e.g. toxins, air pollutants, as well as allergens. These pathogens or pathogen-associated molecular pattern and inflammatory agents e.g. damage-associated molecular pattern cause significant disturbances in the pulmonary barrier. The physiological and biological functions, as well as the architecture and homeostatic maintenance of the pulmonary barrier are highly complex. The airway epithelium, denoting the first pulmonary barrier, encompasses cells releasing a plethora of chemokines and cytokines, and is further covered with a mucus layer containing antimicrobial peptides, which are responsible for the pathogen clearance. Submucosal antigen-presenting cells and neutrophilic granulocytes are also involved in the defense mechanisms and counterregulation of pulmonary infections, and thus may directly affect the pulmonary barrier function. The detailed understanding of the pulmonary barrier including its architecture and functions is crucial for the diagnosis, prognosis, and therapeutic treatment strategies of pulmonary diseases. Thus, considering multiple side effects and limited efficacy of current therapeutic treatment strategies in patients with inflammatory diseases make experimental

Indexed as

LungPneumoniaAir PollutantsAntigen-Presenting CellsAntimicrobial PeptidesChemokinesCytokinesGranulocytesHumansMucusAir PollutantsAntimicrobial PeptidesChemokinesCytokines2D3Dair-liquidALIco-cultureLOACorganoidPCLS

Identifiers

PMID35874776
PMCPMC9300899
OpenAlexW4284676906

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.